S. Cattan

539 total citations
17 papers, 425 citations indexed

About

S. Cattan is a scholar working on Oncology, Epidemiology and Hepatology. According to data from OpenAlex, S. Cattan has authored 17 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Epidemiology and 6 papers in Hepatology. Recurrent topics in S. Cattan's work include Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). S. Cattan is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). S. Cattan collaborates with scholars based in France, United States and Taiwan. S. Cattan's co-authors include Jean–Pierre Gendre, Franck Carbonnel, Laurent Beaugerie, Jacques Cosnes, Antoine Blain, Géraldine Sergent, Olivier Ernst, Emmanuel Boleslawski, F.-R. Pruvot and Antoine Hollebecque and has published in prestigious journals such as Journal of Clinical Oncology, Gut and Journal of Hepatology.

In The Last Decade

S. Cattan

15 papers receiving 418 citations

Peers

Countries citing papers authored by S. Cattan

Since Specialization

Citations

This map shows the geographic impact of S. Cattan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Cattan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Cattan more than expected).

Fields of papers citing papers by S. Cattan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Cattan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Cattan. The network helps show where S. Cattan may publish in the future.

Co-authorship network of co-authors of S. Cattan

This figure shows the co-authorship network connecting the top 25 collaborators of S. Cattan. A scholar is included among the top collaborators of S. Cattan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Cattan. S. Cattan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	933P Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study 2021 ·Annals of Oncology ·J-L. van Laethem, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stål, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, S. Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, (unknown), Michael Chisamore, A. Wang, Andrew X. Zhu	1
2	Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC) 2018 ·Annals of Oncology ·Robin Kate Kelley, Anthony B. El-Khoueiry, Tim Meyer, Lorenza Rimassa, Philippe Merle, Stephen L. Chan, Albert Tran, Francis Parnis, Vincent C. Tam, S. Cattan, David W. Markby, D O Clary, Ann‐Lii Cheng, Ghassan K. Abou‐Alfa	9
3	Quand perte de sens rime avec souffrance : analyse qualitative du vécu des médecins à l’annonce d’une mauvaise nouvelle en oncologie 2015 ·Psycho-Oncologie ·(unknown), Pascal Antoine, S. Cattan, Véronique Christophe	1
4	Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score 2011 ·Alimentary Pharmacology & Therapeutics ·Antoine Hollebecque, S. Cattan, (unknown), Géraldine Sergent, Abbas Mourad, Alexandre Louvet, Sébastien Dharancy, Emmanuel Boleslawski, Stéphanie Truant, F.-R. Pruvot, Mohamed Hebbar, Olivier Ernst, Philippe Mathurin	89
5	626 ASSESSMENT OF RESPONSE TO SORAFENIB IN HEPATOCELLULAR CARCINOMA: PROGNOSTIC VALUE OF TUMORAL DENSITY AND ARTERIAL ENHANCEMENT MEASUREMENTS IN TARGET LESIONS 2011 ·Journal of Hepatology ·Gary Levy, S. Cattan, Géraldine Sergent, (unknown), Sébastien Dharancy, V. Canva-Delcambre, Emmanuel Boleslawski, Stéphanie Truant, Mohamed Hebbar, F.R. Pruvot, (unknown), Philippe Mathurin, Olivier Ernst	1
6	Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301) 2010 ·Gut ·Laëtitia Dahan, Franck Bonnetain, Marc Ychou, Emmanuel Mitry, Mohamed Gasmi, Jean‐Luc Raoul, S. Cattan, Jean–Marc Phelip, Pascal Hammel, Bruno Chauffert, Pierre Michel, Jean-Louis Legoux, P. Rougier, Laurent Bedenne, Jean‐François Seitz, (unknown)	66
7	66 PROSPECTIVE EVALUATION OF SORAFENIB (SO) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): DOES CHILD SCORE B INFLUENCE SAFETY? 2009 ·Journal of Hepatology ·(unknown), S. Cattan, Sébastien Dharancy, V. Canva, Hélène Castel, Emmanuel Boleslawski, Stéphanie Truant, Mohamed Hebbar, F.R. Pruvot, Philippe Mathurin	1
8	CO.46 Fréquence et prise en charge thérapeutique de la toxicité cutanée du sorafenib dans le carcinome hépatocellulaire 2009 ·Gastroentérologie Clinique et Biologique ·(unknown), S. Cattan, Mohamed Hebbar, Sébastien Dharancy, Philippe Mathurin, V. Canva, Alexandre Louvet, Laurent Mortier, (unknown)	1
9	Quelle perception les praticiens ont-ils de l'annonce de mauvaises nouvelles en oncologie ? Analyse qualitative du vécu et des stratégies de régulation émotionnelle What is the physicians' perception on giving bad news in oncology? Qualitative analysis of the emotional experience and emotional regulation strategies 2009 ·(unknown), Véronique Christophe, Pascal Antoine, S. Cattan	0
10	Quelle perception les praticiens ont-ils de l’annonce de mauvaises nouvelles en oncologie ? Analyse qualitative du vécu et des stratégies de régulation émotionnelle 2009 ·Psycho-Oncologie ·(unknown), Véronique Christophe, Pascal Antoine, S. Cattan, Jean‐Louis Nandrino	4
11	Entendre l’annonce du cancer 2004 ·Éthique & Santé ·S. Cattan	2
12	Multicentric phase II study of epirubicin and docetaxel as first line treatment for patients with advanced gastric cancer: A GERCOR study 2004 ·Journal of Clinical Oncology ·(unknown), M. Flesch, Mohammed Bennamoun, Françoise Galateau-Sallé, (unknown), Élisabeth Carola, Jean François Berdah, S. Cattan, E. Magherini, Christophe Louvet	1
13	Crohn's disease clinical course and severity in obese patients 2002 ·Clinical Nutrition ·Antoine Blain, S. Cattan, Laurent Beaugerie, Franck Carbonnel, Jean–Pierre Gendre, Jacques Cosnes	186
14	Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM) 2001 ·Annals of Oncology ·Christophe Louvet, Thierry André, Pascal Hammel, Frédèric Selle, B. Landi, S. Cattan, Marianne Fonck, M. Flesch, Philippe Colin, Jacques Balosso, Philippe Ruszniewski, Aimery de Gramont	33
15	Hepatocellular carcinoma and focal hepatic glycogenosis after prolonged azathioprine therapy 2000 ·Human Pathology ·S. Cattan, Dominique Wendum, Olivier Chazouillères, Jacques Schmitz, Jean–Pierre Gendre	26
16	[Contribution of telemedicine applied to digestive cancer]. 1999 ·PubMed ·A Sézeur, Armand de Gramont, E. Touboul, Laurent Beaugerie, Denis Gallot, S. Cattan, (unknown), Franck Carbonnel, (unknown), (unknown), Christophe Louvet, Jacques Cosnes, M. Housset, M Malafosse	4
17	A propos d'un cas d'adénome parathyroïdien médiastinal traité par embolisation 1982 ·La Revue de Médecine Interne ·Alain Raynaud, J Guéris, (unknown), (unknown), S. Cattan, (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact